Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1991 3
1992 1
1993 3
1995 1
1996 1
1997 3
1998 2
1999 3
2000 1
2001 1
2002 3
2003 2
2004 2
2005 9
2006 6
2007 4
2008 9
2009 16
2010 11
2011 14
2012 17
2013 13
2014 11
2015 11
2016 14
2017 6
2018 5
2019 12
2020 15
2021 17
2022 10
2023 3
Text availability
Article attribute
Article type
Publication date

Search Results

192 results
Results by year
Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I; DESTINY-Breast01 Investigators. Modi S, et al. Among authors: aogi k. N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11. N Engl J Med. 2020. PMID: 31825192 Free PMC article. Clinical Trial.
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park KH, Sasano H, Ohashi Y, Toi M. Masuda N, et al. Among authors: aogi k. N Engl J Med. 2017 Jun 1;376(22):2147-2159. doi: 10.1056/NEJMoa1612645. N Engl J Med. 2017. PMID: 28564564 Free article. Clinical Trial.
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.
Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Shimizu A, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Kinoshita T, Kai Y, Kitada M, Sato Y, Jimbo K, Sato N, Ishiguro H, Takada M, Ohashi Y, Ohno S. Toi M, et al. Among authors: aogi k. Lancet Oncol. 2021 Jan;22(1):74-84. doi: 10.1016/S1470-2045(20)30534-9. Lancet Oncol. 2021. PMID: 33387497 Clinical Trial.
Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.
Ueno T, Kitano S, Masuda N, Ikarashi D, Yamashita M, Chiba T, Kadoya T, Bando H, Yamanaka T, Ohtani S, Nagai S, Nakayama T, Takahashi M, Saji S, Aogi K, Velaga R, Kawaguchi K, Morita S, Haga H, Ohno S, Toi M. Ueno T, et al. Among authors: aogi k. BMC Med. 2022 Apr 25;20(1):136. doi: 10.1186/s12916-022-02332-1. BMC Med. 2022. PMID: 35462552 Free PMC article.
Prognosis and effectiveness of chemotherapy for medullary breast carcinoma.
Aihara T, Kumamaru H, Ishitobi M, Miyashita M, Miyata H, Tamura K, Yoshida M, Ogo E, Nagahashi M, Asaga S, Kojima Y, Kadoya T, Aogi K, Niikura N, Iijima K, Hayashi N, Kubo M, Yamamoto Y, Takeuchi Y, Imoto S, Jinno H. Aihara T, et al. Among authors: aogi k. Breast Cancer Res Treat. 2022 Dec;196(3):635-645. doi: 10.1007/s10549-022-06749-3. Epub 2022 Oct 23. Breast Cancer Res Treat. 2022. PMID: 36273358
Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
Aogi K, Watanabe K, Kitada M, Sangai T, Ohtani S, Aruga T, Kawaguchi H, Fujisawa T, Maeda S, Morimoto T, Sato N, Takao S, Morita S, Masuda N, Toi M, Ohno S. Aogi K, et al. Int J Clin Oncol. 2022 Nov;27(11):1793. doi: 10.1007/s10147-022-02237-2. Int J Clin Oncol. 2022. PMID: 36166110 Free PMC article. No abstract available.
Clinicopathological features of male patients with breast cancer based on a nationwide registry database in Japan.
Shimomura A, Nagahashi M, Kumamaru H, Aogi K, Asaga S, Hayashi N, Iijima K, Kadoya T, Kojima Y, Kubo M, Miyashita M, Miyata H, Niikura N, Ogo E, Tamura K, Tanakura K, Yoshida M, Yamamoto Y, Imoto S, Jinno H. Shimomura A, et al. Among authors: aogi k. Breast Cancer. 2022 Nov;29(6):985-992. doi: 10.1007/s12282-022-01378-6. Epub 2022 Jun 22. Breast Cancer. 2022. PMID: 35733033 Free PMC article.
192 results